Marina Popova1, Tatiana Soboleva1, Suliman Ayad2, Abby D Benninghoff3, Lisa M Berreau1. 1. Department of Chemistry & Biochemistry , Utah State University , 0300 Old Main Hill , Logan , Utah 84322-0300 , United States. 2. Department of Chemistry & Biochemistry , Florida State University , Tallahassee , Florida 32306-4390 , United States. 3. Department of Animal, Dairy and Veterinary Sciences , Utah State University , Logan , Utah 84322-4815 , United States.
Abstract
The delivery of controlled amounts of carbon monoxide (CO) to biological targets is of significant current interest. Very few CO-releasing compounds are currently known that can be rigorously controlled in terms of the location and amount of CO released. To address this deficiency, we report herein a new metal-free, visible-light-induced CO-releasing molecule (photoCORM) and its prodrug oxidized form, which offer new approaches to controlled, localized CO delivery. The new photoCORM, based on a 3-hydroxybenzo[ g]quinolone framework, releases 1 equiv of CO upon visible-light illumination under a variety of biologically relevant conditions. This nontoxic compound can be tracked prior to CO release using fluorescence microscopy and produces a nontoxic byproduct following CO release. An oxidized prodrug form of the photoCORM is reduced by cellular thiols, providing an approach toward activation in the reducing environment of cancer cells. Strong noncovalent affinity of the nonmetal photoCORM to albumin enables use of an albumin:photoCORM complex for targeted CO delivery to cancer cells. This approach produced cytotoxicity IC50 values among the lowest reported to date for CO delivery to cancer cells by a photoCORM. This albumin:photoCORM complex is also the first CO delivery system to produce significant anti-inflammatory effects when introduced at nanomolar photoCORM concentration.
The delivery of controlled amounts of n class="Chemical">carbon monoxide (CO) to biological targets is of significant current interest. Very few CO-releasing compounds are currently known that can be rigorously controlled in terms of the location and amount of CO released. To address this deficiency, we report herein a new metal-free, visible-light-induced CO-releasing molecule (photoCORM) and its prodrug oxidized form, which offer new approaches to controlled, localized CO delivery. The new photoCORM, based on a 3-hydroxybenzo[ g]quinolone framework, releases 1 equiv of CO upon visible-light illumination under a variety of biologically relevant conditions. This nontoxic compound can be tracked prior to CO release using fluorescence microscopy and produces a nontoxic byproduct following CO release. An oxidized prodrug form of the photoCORM is reduced by cellular thiols, providing an approach toward activation in the reducing environment of cancer cells. Strong noncovalent affinity of the nonmetal photoCORM to albumin enables use of an albumin:photoCORM complex for targeted CO delivery to cancer cells. This approach produced cytotoxicity IC50 values among the lowest reported to date for CO delivery to cancer cells by a photoCORM. This albumin:photoCORM complex is also the first CO delivery system to produce significant anti-inflammatory effects when introduced at nanomolar photoCORM concentration.
Authors: Lovely Angel Panamparambil Antony; Tomáš Slanina; Peter Šebej; Tomáš Šolomek; Petr Klán Journal: Org Lett Date: 2013-08-19 Impact factor: 6.005
Authors: Samantha J Carrington; Indranil Chakraborty; Jenna M L Bernard; Pradip K Mascharak Journal: ACS Med Chem Lett Date: 2014-11-17 Impact factor: 4.345
Authors: Neil Desai; Vuong Trieu; Zhiwen Yao; Leslie Louie; Sherry Ci; Andrew Yang; Chunlin Tao; Tapas De; Bridget Beals; Donald Dykes; Patricia Noker; Rosie Yao; Elizabeth Labao; Michael Hawkins; Patrick Soon-Shiong Journal: Clin Cancer Res Date: 2006-02-15 Impact factor: 12.531
Authors: Ine Rombouts; Bert Lagrain; Katharina A Scherf; Marlies A Lambrecht; Peter Koehler; Jan A Delcour Journal: Sci Rep Date: 2015-07-20 Impact factor: 4.379